Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
A quick look at the price chart below shows us that the stock is up 47% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 8.40, which means that it remains undervalued.
Superinvestors who currently hold positions in the company include:
Cliff Asness – 449,619
Jim Simons – 282,962
John Hempton – 130,460
Israel Englander – 124,794
Ken Griffin – 99,920
Tom Gayner – 79,300
Catherine Wood – 72,993
Joel Greenblatt – 23,664
Ray Dalio – 7,535
Ken Fisher – 5,216
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple: